For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or ...

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

Canada India Tech Council, in partnership with Consulate General of India (Toronto) and TheAppLabb, is proud to announce the ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

VEOCELtm, the flagship specialty nonwovens brand of Lenzing Group, highlighted its commitment to innovation and providing solutions to help address the global plastic crisis at the "SEA of Solutions ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of ...

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of the lymph nodes. The development of novel targeted therapies and ...

Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious ...

Pembrolizumab - branded as Keytruda - will be funded from October 1, 2024, for eligible people with advanced triple-negative ...